Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 122 participants.

Also called NCT01564875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01564875
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01564875. Randomized; triple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
Acronym
HM-SIM4
Condition
Hyperlipidemia
Intervention (Drug)
Simvast CR
Intervention (Drug)
Zocor
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct01564875
Content hash
4511912afc9fc220d2a647a6b9bdad6879026196c596db0a5ee3e2973a243de5